Abstract
Increasing treatment specificity is one of the major aims of cancer research. Photodynamic therapy is a clinically proven treatment for some cancers and certain other diseases. Photosensitisers generally have little intrinsic selectivity for tumours and any accumulation is dependent upon the type of tumour involved. Increasing tumour selective accumulation could improve the efficacy of PDT and reduce any risk of side effects caused by photosensitiser accumulation in non-target tissue. In order to target photosensitisers to tumours, a cyclic peptide, cRGDfK (arginine-glycine-aspartic acid-phenylalanine-lysine) has been synthesised using solid phase peptide chemistry and conjugated to the porphyrin photosensitiser, protoporphyrin IX. The arginine-glycine-aspartic acid (RGD) motif has been shown to specifically bind αvβ3 integrins, heterodimeric glycoproteins upregulated on the surface of proliferating endothelial cells such as those in tumour neovasculature. This study reports the synthesis, in vitro and in vivo characterisation of this novel compound and compares its properties to the free photosensitiser. The individual components in our system, protoporphyrin IX and cRGDfK retain their respective photodynamic and integrin binding activity following the coupling step and produce a conjugate of high purity. The PpIX:cRGDfK conjugate is shown to be a good photosensitiser in vitro in the integrin positive human SiHa cell line and in vivo in a mouse CaNT tumour model. Moreover, pharmacokinetic analysis of PpIX:cRGDfK treated mice shows significant retention and accumulation of photosensitiser in tumour tissue with higher tumour : normal tissue ratios than the free photosensitiser. However, although the conjugate shows this higher accumulation and improved tumour : non-target tissue ratios, the overall in vivo PDT effect, between dose-light intervals of 0 and 6 h, is not significantly better than for free protoporphyrin IX This is possibly due to differences in the target environment or in the subcellular localisation of the compounds.
Similar content being viewed by others
References
S. B. Brown, E. A. Brown and I. Walker, The present and future role of photodynamic therapy in cancer treatment, Lancet Oncol., 2004, 5, 497–508.
D. E. Dolmans, D. Fukumura and R. K. Jain, Photodynamic therapy for cancer, Nat. Rev. Cancer, 2003, 3, 380–387.
T. J. Dougherty, C. J. Gomer, B. W. Henderson, G. Jori, D. Kessel, M. Korbelik, J. Moan and Q. Peng, Photodynamic therapy, J. Natl. Cancer Inst., 1998, 90, 889–905.
G. Jori, C. Fabris, M. Soncin, S. Ferro, O. Coppellotti, D. Dei, L. Fantetti, G. Chiti and G. Roncucci, Photodynamic therapy in the treatment of microbial infections: basic principles and perspective applications, Lasers Surg. Med., 2006, 38, 468–481.
T. Maisch, R. M. Szeimies, G. Jori, C. Abels, L. Madden, O. J. Clarke, A. Pelegrin, J. Greenman and R. W. Boyle, Antibacterial photodynamic therapy in dermatology, Photochem. Photobiol. Sci., 2004, 3, 907–917.
R. Hudson and R. W. Boyle, Strategies for selective delivery of photodynamic sensitisers to biological targets, J. Porphyrins Phthalocyanines, 2004, 8, 954–975.
A. M. Richter, E. Waterfield, A. K. Jain, A. J. Canaan, B. A. Allison and J. G. Levy, Liposomal, delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), to tumor tissue in a mouse tumor model, Photochem. Photobiol., 1993, 57, 1000–1006.
K. Kurohane, A. Tominaga, K. Sato, J. R. North, Y. Namba and N. Oku, Photodynamic therapy targeted to tumor-induced angiogenic vessels, Cancer Lett., 2001, 167, 49–56.
E. Allemann, J. Rousseau, N. Brasseur, S. V. Kudrevich, K. Lewis, J. E. van Lier, Photodynamic therapy of tumours with hexadecafluoro zinc phthalocynine formulated in PEG-coated poly(lactic acid) nanoparticles, Int. J. Cancer, 1996, 66, 821–824.
N. Swamy, D. A. James, S. C. Mohr, R. N. Hanson and R. Ray, An estradiol-porphyrin conjugate selectively localizes into estrogen receptor-positive breast cancer cells, Bioorg. Med. Chem., 2002, 10, 3237–3243.
G. A. van Dongen, G. W. Visser and M. B. Vrouenraets, Photosensitizer-antibody conjugates for detection and therapy of cancer, Adv. Drug Deliv. Rev., 2004, 56, 31–52.
N. Malatesti, K. Smith, H. Savoie, J. Greenman and R. W. Boyle, Synthesis, and in vitro investigation of cationic 5,15-diphenyl porphyrin-monoclonal antibody conjugates as targeted photodynamic sensitisers, Int. J. Oncol., 2006, 28, 1561–1569.
R. Hudson, M. Carcenac, K. Smith, L. Madden, O. J. Clarke, A. Pelegrin, J. Greenman and R. W. Boyle, The development and characterisation of porphyrin isothiocyanate-monoclonal antibody conjugates for photoimmunotherapy, Br. J. Cancer, 2005, 92, 1442–1449.
C. Staneloudi, K. A. Smith, R. Hudson, N. Malatesti, H. Savoie, R. W. Boyle and J. Greenman, Development and characterization of novel photosensitizer: scFv conjugates for use in photodynamic therapy of cancer, Immunology, 2007, 120, 512–517.
M. B. Vrouenraets, G. W. Visser, F. A. Stewart, M. Stigter, H. Oppelaar, P. E. Postmus, G. B. Snow, G. A van Dongen, Development of meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for photoimmunotherapy, Cancer Res., 1999, 59, 1505–1513.
T. Boehm, J. Folkman, T. Browder and M. S. O’Reilly, Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance, Nature, 1997, 390, 404–407.
K. Ichikawa, T. Hikita, N. Maeda, S. Yonezawa, Y. Takeuchi, T. Asai, Y. Namba and N. Oku, Antiangiogenic photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific to angiogenic vessels, Biochim. Biophys. Acta, 2005, 1669, 69–74.
R. Max, R. R. Gerritsen, P. T. Nooijen, S. L. Goodman, A. Sutter, U. Keilholz, D. J. Ruiter, R. M. de Waal, Immunohistochemical analysis of integrin alpha v beta 3 expression on tumor-associated vessels of human carcinomas, Int. J. Cancer, 1997, 71, 320–324.
P. C. Brooks, R. A. Clark and D. A. Cheresh, Requirement of vascular integrin alpha v beta 3 for angiogenesis, Science, 1994, 264, 569–571.
M. D. Pierschbacher and E. Ruoslahti, Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule, Nature, 1984, 309, 30–33.
E. Ruoslahti, The RGD story: a personal account, Matrix Biol., 2003, 22, 459–465.
E. Ruoslahti, RGD, and other recognition sequences for integrins, Annu. Rev. Cell Dev. Biol., 1996, 12, 697–715.
M. D. Pierschbacher and E. Ruoslahti, Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion, J. Biol. Chem., 1987, 262, 17294–17298.
M. Aumailley, M. Gurrath, G. Muller, J. Calvete, R. Timpl and H. Kessler, Arg-Gly-Asp, constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1, FEBS Lett., 1991, 291, 50–54.
C. F. McCusker, P. J. Kocienski, F. T. Boyle and A. G. Schatzlein, Solid-phase synthesis of c(RGDfK) derivatives: on-resin cyclisation and lysine functionalisation, Bioorg. Med. Chem. Lett., 2002, 12, 547–549.
S. Verrier, S. Pallu, R. Bareille, A. Jonczyk, J. Meyer, M. Dard and J. Amedee, Function of linear and cyclic RGD-containing peptides in osteoprogenitor cells adhesion process, Biomaterials, 2002, 23, 585–596.
R. Haubner and H. J. Wester, Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies, Curr. Pharm. Des., 2004, 10, 1439–1455.
W. Arap, R. Pasqualini and E. Ruoslahti, Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model, Science, 1998, 279, 377–380.
X. Chen, C. Plasencia, Y. Hou and N. Neamati, Synthesis and biological evaluation of dimeric RGD peptide–paclitaxel conjugate as a model for integrin-targeted drug delivery, J. Med. Chem., 2005, 48, 1098–1106.
H. M. Ellerby, W. Arap, L. M. Ellerby, R. Kain, R. Andrusiak, G. D. Rio, S. Krajewski, C. R. Lombardo, R. Rao, E. Ruoslahti, D. E. Bredesen and R. Pasqualini, Anti-cancer activity of targeted pro-apoptotic peptides, Nat. Med., 1999, 5, 1032–1038.
C. Frochot, B. D. Stasio, R. Vanderesse, M. J. Belgy, M. Dodeller, F. Guillemin, M. L. Viriot and M. Barberi-Heyob, Interest of RGD-containing linear or cyclic peptide targeted tetraphenylchlorin as novel photosensitizers for selective photodynamic activity, Bioorg. Chem., 2006, 35, 205–220.
I. Walker, D. I. Vernon and S. B. Brown, The solid-phase conjugation of purpurin-18 with a synthetic targeting peptide, Bioorg. Med. Chem. Lett., 2004, 14, 441–443.
N. Chatterjee and A. Chatterjee, Role of alpha v beta 3 integrin receptor in the invasive potential of human cervical cancer (SiHa) cells, J. Environ. Pathol. Toxicol. Oncol., 2001, 20, 211–221.
A. J. Schraa, R. J. Kok, A. D. Berendsen, H. E. Moorlag, E. J. Bos, D. K. Meijer, L. F. de Leij and G. Molema, Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting, J. Controlled Release, 2002, 83, 241–251.
P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J. T. Warren, H. Bokesch, S. Kenney and M. R. Boyd, New colorimetric cytotoxicity assay for anticancer-drug screening, J. Natl. Cancer Inst., 1990, 82, 1107–1112.
Y. OH. Lowry, N. J. Rosebrough, A. L. Farr and R. J. Randall, Protein measurement with the Folin phenol reagent, J. Biol. Chem., 1951, 193, 265–275.
H. B. Hewitt, E. Blake and E. H. Proter, The effect of lethally irradiated cells on the transplantability of murine tumours, Br. J. Cancer, 1973, 28, 123–135.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Conway, C.L., Walker, I., Bell, A. et al. In vivo and in vitro characterisation of a protoporphyrin IX-cyclic RGD peptide conjugate for use in photodynamic therapy. Photochem Photobiol Sci 7, 290–298 (2008). https://doi.org/10.1039/b715141a
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1039/b715141a